IKT — Inhibikase Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1750149 ·
Last close
$1.38
Market Cap
$193.57M
52W High
$2.61
52W Low
$1.37
ADV30
641,741
Next earnings
2026-11-10
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -22,229,057 -20,467,334 201,751,949 51,701,197 12,956,751
Jun 2026 0 — -21,050,995 -19,591,231 163,588,612 31,206,707 10,260,026
Mar 2026 0 — -18,215,273 -16,380,840 173,332,227 49,573,510 5,711,959
Dec 2025 0 — -13,133,457 -12,734,651 181,204,516 139,220,208 8,300,837

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-49,371,537
Investing CF
$-99,102,650
Financing CF
$161,905,678
CapEx
$-452,023
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.44
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-199,119,205
Inventory
—
Receivables
—
ST Investments
$141,619,768
EBIT TTM
$-74,628,782
Pretax Income TTM
$-69,174,056
Interest Exp TTM
—
Analysts
10

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -53,348,225 -48,259,189 181,204,516 8,300,837 172,903,679 -27,786,464
Dec 2024 0 -28,589,068 -27,519,886 98,599,846 3,733,566 94,866,280 -19,148,067
Dec 2023 0 -20,089,792 -19,028,883 14,506,647 3,528,725 10,977,922 -18,085,043
Dec 2022 0 -18,128,608 -18,054,155 24,936,297 3,900,896 21,035,401 -17,351,103

TTM Snapshot

Revenues TTM
$84,512,107
NetIncome TTM
$-60,637,002
OpCashFlow TTM
—
Assets (Latest)
$163,588,612
Forward EPS
$-0.41

Peers — same industry

TickerNameMarket CapLastDaily %
CGEN COMPUGEN LTD $191.34M $2.02 —
ARTV Artiva Biotherapeutics, Inc. $190.81M $3.86 —
DTIL PRECISION BIOSCIENCES INC $196.95M $7.05 —
LCTX Lineage Cell Therapeutics, Inc. $206.36M $0.82 —
PALI PALISADE BIO, INC. $181.07M $1.01 —

News headlines (Yahoo Finance, 1h cache)

Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity
2026-11-10 21:01 · Yahoo
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
2026-10-27 12:00 · Yahoo
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
2026-10-20 20:01 · Yahoo
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:01 · Yahoo
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
2026-08-11 20:01 · Yahoo
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
2026-07-23 12:00 · Yahoo
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
2026-07-14 12:00 · Yahoo
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
2026-04-07 12:00 · Yahoo
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
2026-05-12 20:01 · Yahoo
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
2026-02-22 11:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.